Search results
Results from the WOW.Com Content Network
The Prescribing Information follows one of two formats: "physician labeling rule" format or "old" (non-PLR) format. For "old" format labeling a "product title" may be listed first and may include the proprietary name (if any), the nonproprietary name, dosage form(s), and other information about the product.
A box of Plavix. Plavix is marketed worldwide in nearly 110 countries, with sales of US$6.6 billion in 2009. [45] It was the second-top-selling drug in the world in 2007 [46] and was still growing by over 20% in 2007. US sales were US$3.8 billion in 2008. [47]
In 2006, Sanofi-Aventis SA and Bristol-Myers Squibb Co., the producers and patent owners of Plavix, the blood thinner drug, settled a patent lawsuit with Apotex. [23] [24] In the settlement, Apotex agreed not to sell a generic version of Plavix until September 2011, in exchange for an unspecified amount of money. [23]
The medication will be sold under the brand name Journavx for $15.50 per pill, according to Vertex Pharmaceuticals, ... of its class to receive federal approval in more than 20 years.
From or to a drug trade name: This is a redirect from (or to) the trade name of a drug to (or from) the international nonproprietary name (INN).
In some countries, such as Brazil (photo) and France, more than 20% of all drug sales in units are generic. A generic drug is a pharmaceutical drug that contains the same chemical substance as a drug that was originally protected by chemical patents. Generic drugs are allowed for sale after the patents on the original drugs expire.
This 1916 advertisement distinguishes the list price and a lower our special price.. The list price, also known as the manufacturer's suggested retail price (MSRP), or the recommended retail price (RRP), or the suggested retail price (SRP) of a product is the price at which its manufacturer notionally recommends that a retailer sell the product.
An antiplatelet drug (antiaggregant), also known as a platelet agglutination inhibitor or platelet aggregation inhibitor, is a member of a class of pharmaceuticals that decrease platelet aggregation [1] and inhibit thrombus formation.